TABLE 2.

Randomized Controlled Trials of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors for Child and Adolescent Anxiety Disorders^a

				Dose (mg/day)
Treatment studied	Diagnosis	Duration (weeks)	N	Range	Average	FDA indication (age 12–17)	Adverse events
Walkup et al., 2008 (74)	GAD, SoP, SAD	12		25–200	133.7±59.8	OCD (50–200 mg/day)b	No suicide attempts, no significantly greater rate of adverse events in sertraline vs. placebo group
Sertraline			133
CBT			139
Combination			140
Placebo			76
Strawn et al., 2015 (101)	GAD	10		30–120	53.6	GAD (30–60 mg/day)b	7 SAEs among 5 participants in acute/extension treatment phase, 1 SAE in taper phase
Duloxetine			135
Placebo			137
Rynn et al., 2001 (102)	GAD	9		50	Fixed dose	OCD	Among treatment group, more adverse events of dry mouth, drowsiness, leg spasms, restlessness
Sertraline			11
Placebo			11
Beidel et al., 2007 (95)	SoP	12		≤40	Average not reported	Major depressive disorder (10–20 mg/day),b OCD (20–60 mg/day)b	No reported suicidal ideation/parasuicidal behavior
Fluoxetine			33
SET			57
Placebo			32
Wagner et al., 2004 (103)	SoP	16		≤50	24.8		4 in treatment group had suicidal ideation or threatened suicide (1 self-harm in addition); 3 occurred during treatment, 1 during follow up; 1 additional self-harm for attention
Paroxetine			163
Placebo			156
March et al., 2007 (104)	SoP	16		37.5–225	141.5±47.5 (for >0 days of exposure), 155±39.0 (for >112 days of exposure)		3 cases of suicidal ideation (treatment group), no suicides or attempts
Venlafaxine ER			137
Placebo			148
RUPP, 2001 (105)	GAD, SoP, SAD	8		300	2.9±1.3 mg/kg	OCD (50–200 mg/day)b	In treatment group, abdominal discomfort higher, trend toward increased motor activity; 5 cases of study withdrawal due to adverse events: sedation, somatic discomfort, or hyperactivity
RUPP, 2001 (105) (continued)
Fluvoxamine			61
Placebo			63
BMS (2010)	GAD	8		15–60	Average not reported
Buspirone
Placebo
Rynn et al., 2007 (106)	GAD	8		37.5–225	Average not reported		4 participants had serious adverse events (2 treatment group, 2 placebo)
Venlafaxine ER			157
Placebo			163

^aGAD, generalized anxiety disorder; SAD, separation anxiety disorder; CBT, cognitive-behavioral therapy; OCD, obsessive-compulsive disorder; ER, extended release; SoP, social phobia; OCD, obsessive-compulsive disorder; SET, social effectiveness therapy; SAE, significant adverse events; RUPP, Research Unit on Pediatric Psychopharmacology Anxiety Study Group; BMS, Bristol-Myers Squibb

^bPediatric dosage range recommended by the Food and Drug Administration (FDA).